;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

Headlines

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

Published by Global Banking and Finance Review

Posted on May 23, 2025

Featured image for article about Headlines

(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's rival treatment Vabysmo.

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema.

(Reporting by Ludwig Burger, Editing by Friederike Heine)

More from Headlines

Explore more articles in the Headlines category

Cyberattack on French interior ministry's email servers compromised more than 20 files

WTO chair rules out reform deal at next major meeting, document shows

EU Parliament approves phase out of Russian gas imports

Putin says Russia will achieve war goals, keep expanding 'buffer zone'

Italy's Meloni says it's still 'premature' to sign EU-Mercosur trade deal

Russian attack on Ukraine's Zaporizhzhia injures 26, governor says

Decline in UK industrial orders eases slightly, CBI says

Italy's Meloni says using frozen Russian assets for Ukraine 'far from easy' ahead of EU summit

UK removes duplicate entries from sanctions lists, designations remain in place

How combative videographers fire up Britain's asylum hotel protests

UK police charge teenage boy with nine-year-old girl's murder

Paris' Louvre reopens partially but staff vote to extend strike

View All Headlines Posts